

Global Infliximab and Biosimilar Market Research Report 2023(Status and Outlook)

<https://marketpublishers.com/r/G578B3BD955AEN.html>

Date: August 2023

Pages: 103

Price: US\$ 3,200.00 (Single User License)

ID: G578B3BD955AEN

Abstracts

Report Overview

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.

Bosson Research's latest report provides a deep insight into the global Infliximab and Biosimilar market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Infliximab and Biosimilar Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Infliximab and Biosimilar market in any manner.

Global Infliximab and Biosimilar Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development

cycles by informing how you create product offerings for different segments.

Key Company

Janssen Biotech

Merck and Co.

Pfizer

Market Segmentation (by Type)

Infliximab

Infliximab-dyyb

Infliximab-abda

Market Segmentation (by Application)

Crohn's Disease

Pediatric Crohn's Disease

Ulcerative Colitis

Rheumatoid Arthritis

Ankylosing Spondylitis

Psoriatic Arthritis

Plaque Psoriasis

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Infliximab and Biosimilar Market

Overview of the regional outlook of the Infliximab and Biosimilar Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Infiximab and Biosimilar Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Infliximab and Biosimilar

1.2 Key Market Segments

1.2.1 Infliximab and Biosimilar Segment by Type

1.2.2 Infliximab and Biosimilar Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 INFLIXIMAB AND BIOSIMILAR MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Infliximab and Biosimilar Market Size (M USD) Estimates and Forecasts (2018-2029)

2.1.2 Global Infliximab and Biosimilar Sales Estimates and Forecasts (2018-2029)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 INFLIXIMAB AND BIOSIMILAR MARKET COMPETITIVE LANDSCAPE

3.1 Global Infliximab and Biosimilar Sales by Manufacturers (2018-2023)

3.2 Global Infliximab and Biosimilar Revenue Market Share by Manufacturers (2018-2023)

3.3 Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Infliximab and Biosimilar Average Price by Manufacturers (2018-2023)

3.5 Manufacturers Infliximab and Biosimilar Sales Sites, Area Served, Product Type

3.6 Infliximab and Biosimilar Market Competitive Situation and Trends

3.6.1 Infliximab and Biosimilar Market Concentration Rate

3.6.2 Global 5 and 10 Largest Infliximab and Biosimilar Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 INFLIXIMAB AND BIOSIMILAR INDUSTRY CHAIN ANALYSIS

- 4.1 Infliximab and Biosimilar Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF INFLIXIMAB AND BIOSIMILAR MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 INFLIXIMAB AND BIOSIMILAR MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Infliximab and Biosimilar Sales Market Share by Type (2018-2023)
- 6.3 Global Infliximab and Biosimilar Market Size Market Share by Type (2018-2023)
- 6.4 Global Infliximab and Biosimilar Price by Type (2018-2023)

7 INFLIXIMAB AND BIOSIMILAR MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Infliximab and Biosimilar Market Sales by Application (2018-2023)
- 7.3 Global Infliximab and Biosimilar Market Size (M USD) by Application (2018-2023)
- 7.4 Global Infliximab and Biosimilar Sales Growth Rate by Application (2018-2023)

8 INFLIXIMAB AND BIOSIMILAR MARKET SEGMENTATION BY REGION

- 8.1 Global Infliximab and Biosimilar Sales by Region
 - 8.1.1 Global Infliximab and Biosimilar Sales by Region
 - 8.1.2 Global Infliximab and Biosimilar Sales Market Share by Region

8.2 North America

8.2.1 North America Infliximab and Biosimilar Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Infliximab and Biosimilar Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Infliximab and Biosimilar Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Infliximab and Biosimilar Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Infliximab and Biosimilar Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Janssen Biotech

9.1.1 Janssen Biotech Infliximab and Biosimilar Basic Information

9.1.2 Janssen Biotech Infliximab and Biosimilar Product Overview

9.1.3 Janssen Biotech Infliximab and Biosimilar Product Market Performance

9.1.4 Janssen Biotech Business Overview

- 9.1.5 Janssen Biotech Infliximab and Biosimilar SWOT Analysis
- 9.1.6 Janssen Biotech Recent Developments
- 9.2 Merck and Co.
 - 9.2.1 Merck and Co. Infliximab and Biosimilar Basic Information
 - 9.2.2 Merck and Co. Infliximab and Biosimilar Product Overview
 - 9.2.3 Merck and Co. Infliximab and Biosimilar Product Market Performance
 - 9.2.4 Merck and Co. Business Overview
 - 9.2.5 Merck and Co. Infliximab and Biosimilar SWOT Analysis
 - 9.2.6 Merck and Co. Recent Developments
- 9.3 Pfizer
 - 9.3.1 Pfizer Infliximab and Biosimilar Basic Information
 - 9.3.2 Pfizer Infliximab and Biosimilar Product Overview
 - 9.3.3 Pfizer Infliximab and Biosimilar Product Market Performance
 - 9.3.4 Pfizer Business Overview
 - 9.3.5 Pfizer Infliximab and Biosimilar SWOT Analysis
 - 9.3.6 Pfizer Recent Developments

10 INFLIXIMAB AND BIOSIMILAR MARKET FORECAST BY REGION

- 10.1 Global Infliximab and Biosimilar Market Size Forecast
- 10.2 Global Infliximab and Biosimilar Market Forecast by Region
 - 10.2.1 North America Market Size Forecast by Country
 - 10.2.2 Europe Infliximab and Biosimilar Market Size Forecast by Country
 - 10.2.3 Asia Pacific Infliximab and Biosimilar Market Size Forecast by Region
 - 10.2.4 South America Infliximab and Biosimilar Market Size Forecast by Country
 - 10.2.5 Middle East and Africa Forecasted Consumption of Infliximab and Biosimilar by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2024-2029)

- 11.1 Global Infliximab and Biosimilar Market Forecast by Type (2024-2029)
 - 11.1.1 Global Forecasted Sales of Infliximab and Biosimilar by Type (2024-2029)
 - 11.1.2 Global Infliximab and Biosimilar Market Size Forecast by Type (2024-2029)
 - 11.1.3 Global Forecasted Price of Infliximab and Biosimilar by Type (2024-2029)
- 11.2 Global Infliximab and Biosimilar Market Forecast by Application (2024-2029)
 - 11.2.1 Global Infliximab and Biosimilar Sales (K MT) Forecast by Application
 - 11.2.2 Global Infliximab and Biosimilar Market Size (M USD) Forecast by Application (2024-2029)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Infliximab and Biosimilar Market Size Comparison by Region (M USD)

Table 5. Global Infliximab and Biosimilar Sales (K MT) by Manufacturers (2018-2023)

Table 6. Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2018-2023)

Table 7. Global Infliximab and Biosimilar Revenue (M USD) by Manufacturers (2018-2023)

Table 8. Global Infliximab and Biosimilar Revenue Share by Manufacturers (2018-2023)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infliximab and Biosimilar as of 2022)

Table 10. Global Market Infliximab and Biosimilar Average Price (USD/MT) of Key Manufacturers (2018-2023)

Table 11. Manufacturers Infliximab and Biosimilar Sales Sites and Area Served

Table 12. Manufacturers Infliximab and Biosimilar Product Type

Table 13. Global Infliximab and Biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Infliximab and Biosimilar

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Infliximab and Biosimilar Market Challenges

Table 22. Market Restraints

Table 23. Global Infliximab and Biosimilar Sales by Type (K MT)

Table 24. Global Infliximab and Biosimilar Market Size by Type (M USD)

Table 25. Global Infliximab and Biosimilar Sales (K MT) by Type (2018-2023)

Table 26. Global Infliximab and Biosimilar Sales Market Share by Type (2018-2023)

Table 27. Global Infliximab and Biosimilar Market Size (M USD) by Type (2018-2023)

Table 28. Global Infliximab and Biosimilar Market Size Share by Type (2018-2023)

Table 29. Global Infliximab and Biosimilar Price (USD/MT) by Type (2018-2023)

Table 30. Global Infliximab and Biosimilar Sales (K MT) by Application

Table 31. Global Infliximab and Biosimilar Market Size by Application
Table 32. Global Infliximab and Biosimilar Sales by Application (2018-2023) & (K MT)
Table 33. Global Infliximab and Biosimilar Sales Market Share by Application (2018-2023)
Table 34. Global Infliximab and Biosimilar Sales by Application (2018-2023) & (M USD)
Table 35. Global Infliximab and Biosimilar Market Share by Application (2018-2023)
Table 36. Global Infliximab and Biosimilar Sales Growth Rate by Application (2018-2023)
Table 37. Global Infliximab and Biosimilar Sales by Region (2018-2023) & (K MT)
Table 38. Global Infliximab and Biosimilar Sales Market Share by Region (2018-2023)
Table 39. North America Infliximab and Biosimilar Sales by Country (2018-2023) & (K MT)
Table 40. Europe Infliximab and Biosimilar Sales by Country (2018-2023) & (K MT)
Table 41. Asia Pacific Infliximab and Biosimilar Sales by Region (2018-2023) & (K MT)
Table 42. South America Infliximab and Biosimilar Sales by Country (2018-2023) & (K MT)
Table 43. Middle East and Africa Infliximab and Biosimilar Sales by Region (2018-2023) & (K MT)
Table 44. Janssen Biotech Infliximab and Biosimilar Basic Information
Table 45. Janssen Biotech Infliximab and Biosimilar Product Overview
Table 46. Janssen Biotech Infliximab and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 47. Janssen Biotech Business Overview
Table 48. Janssen Biotech Infliximab and Biosimilar SWOT Analysis
Table 49. Janssen Biotech Recent Developments
Table 50. Merck and Co. Infliximab and Biosimilar Basic Information
Table 51. Merck and Co. Infliximab and Biosimilar Product Overview
Table 52. Merck and Co. Infliximab and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 53. Merck and Co. Business Overview
Table 54. Merck and Co. Infliximab and Biosimilar SWOT Analysis
Table 55. Merck and Co. Recent Developments
Table 56. Pfizer Infliximab and Biosimilar Basic Information
Table 57. Pfizer Infliximab and Biosimilar Product Overview
Table 58. Pfizer Infliximab and Biosimilar Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2018-2023)
Table 59. Pfizer Business Overview
Table 60. Pfizer Infliximab and Biosimilar SWOT Analysis
Table 61. Pfizer Recent Developments

Table 62. Global Infliximab and Biosimilar Sales Forecast by Region (2024-2029) & (K MT)

Table 63. Global Infliximab and Biosimilar Market Size Forecast by Region (2024-2029) & (M USD)

Table 64. North America Infliximab and Biosimilar Sales Forecast by Country (2024-2029) & (K MT)

Table 65. North America Infliximab and Biosimilar Market Size Forecast by Country (2024-2029) & (M USD)

Table 66. Europe Infliximab and Biosimilar Sales Forecast by Country (2024-2029) & (K MT)

Table 67. Europe Infliximab and Biosimilar Market Size Forecast by Country (2024-2029) & (M USD)

Table 68. Asia Pacific Infliximab and Biosimilar Sales Forecast by Region (2024-2029) & (K MT)

Table 69. Asia Pacific Infliximab and Biosimilar Market Size Forecast by Region (2024-2029) & (M USD)

Table 70. South America Infliximab and Biosimilar Sales Forecast by Country (2024-2029) & (K MT)

Table 71. South America Infliximab and Biosimilar Market Size Forecast by Country (2024-2029) & (M USD)

Table 72. Middle East and Africa Infliximab and Biosimilar Consumption Forecast by Country (2024-2029) & (Units)

Table 73. Middle East and Africa Infliximab and Biosimilar Market Size Forecast by Country (2024-2029) & (M USD)

Table 74. Global Infliximab and Biosimilar Sales Forecast by Type (2024-2029) & (K MT)

Table 75. Global Infliximab and Biosimilar Market Size Forecast by Type (2024-2029) & (M USD)

Table 76. Global Infliximab and Biosimilar Price Forecast by Type (2024-2029) & (USD/MT)

Table 77. Global Infliximab and Biosimilar Sales (K MT) Forecast by Application (2024-2029)

Table 78. Global Infliximab and Biosimilar Market Size Forecast by Application (2024-2029) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Infliximab and Biosimilar

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Infliximab and Biosimilar Market Size (M USD), 2018-2029

Figure 5. Global Infliximab and Biosimilar Market Size (M USD) (2018-2029)

Figure 6. Global Infliximab and Biosimilar Sales (K MT) & (2018-2029)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Infliximab and Biosimilar Market Size by Country (M USD)

Figure 11. Infliximab and Biosimilar Sales Share by Manufacturers in 2022

Figure 12. Global Infliximab and Biosimilar Revenue Share by Manufacturers in 2022

Figure 13. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 Vs 2022

Figure 14. Global Market Infliximab and Biosimilar Average Price (USD/MT) of Key Manufacturers in 2022

Figure 15. The Global 5 and 10 Largest Players: Market Share by Infliximab and Biosimilar Revenue in 2022

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Infliximab and Biosimilar Market Share by Type

Figure 18. Sales Market Share of Infliximab and Biosimilar by Type (2018-2023)

Figure 19. Sales Market Share of Infliximab and Biosimilar by Type in 2022

Figure 20. Market Size Share of Infliximab and Biosimilar by Type (2018-2023)

Figure 21. Market Size Market Share of Infliximab and Biosimilar by Type in 2022

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Infliximab and Biosimilar Market Share by Application

Figure 24. Global Infliximab and Biosimilar Sales Market Share by Application (2018-2023)

Figure 25. Global Infliximab and Biosimilar Sales Market Share by Application in 2022

Figure 26. Global Infliximab and Biosimilar Market Share by Application (2018-2023)

Figure 27. Global Infliximab and Biosimilar Market Share by Application in 2022

Figure 28. Global Infliximab and Biosimilar Sales Growth Rate by Application (2018-2023)

Figure 29. Global Infliximab and Biosimilar Sales Market Share by Region (2018-2023)

Figure 30. North America Infliximab and Biosimilar Sales and Growth Rate (2018-2023)

& (K MT)

Figure 31. North America Infliximab and Biosimilar Sales Market Share by Country in 2022

Figure 32. U.S. Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 33. Canada Infliximab and Biosimilar Sales (K MT) and Growth Rate (2018-2023)

Figure 34. Mexico Infliximab and Biosimilar Sales (Units) and Growth Rate (2018-2023)

Figure 35. Europe Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 36. Europe Infliximab and Biosimilar Sales Market Share by Country in 2022

Figure 37. Germany Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 38. France Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 39. U.K. Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 40. Italy Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 41. Russia Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 42. Asia Pacific Infliximab and Biosimilar Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Infliximab and Biosimilar Sales Market Share by Region in 2022

Figure 44. China Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 45. Japan Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 46. South Korea Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 47. India Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 48. Southeast Asia Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 49. South America Infliximab and Biosimilar Sales and Growth Rate (K MT)

Figure 50. South America Infliximab and Biosimilar Sales Market Share by Country in 2022

Figure 51. Brazil Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 52. Argentina Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 53. Columbia Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 54. Middle East and Africa Infliximab and Biosimilar Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Infliximab and Biosimilar Sales Market Share by Region in 2022

Figure 56. Saudi Arabia Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 57. UAE Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 58. Egypt Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 59. Nigeria Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 60. South Africa Infliximab and Biosimilar Sales and Growth Rate (2018-2023) & (K MT)

Figure 61. Global Infliximab and Biosimilar Sales Forecast by Volume (2018-2029) & (K MT)

Figure 62. Global Infliximab and Biosimilar Market Size Forecast by Value (2018-2029) & (M USD)

Figure 63. Global Infliximab and Biosimilar Sales Market Share Forecast by Type (2024-2029)

Figure 64. Global Infliximab and Biosimilar Market Share Forecast by Type (2024-2029)

Figure 65. Global Infliximab and Biosimilar Sales Forecast by Application (2024-2029)

Figure 66. Global Infliximab and Biosimilar Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Infliximab and Biosimilar Market Research Report 2023(Status and Outlook)

Product link: <https://marketpublishers.com/r/G578B3BD955AEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G578B3BD955AEN.html>